Meili Technology: Meili, a wholly-owned subsidiary, plans to purchase assets related to MSSC AHLE GmbH for 8.1 million euros. Meili, a wholly-owned subsidiary of Meili Technology, signed an Asset Purchase Agreement with MSSC AHLE GmbH(AHLE Company) on December 10, 2024 to purchase assets related to AHLE Company's business at a transaction consideration of 8.1 million euros, including factory buildings, production equipment, inventory, intangible assets, contractual rights, etc. AHLE Company was established in 1904, and its main business is spring research and development, manufacturing, sales and trade, etc. Its main products include automobile suspension springs, brake chamber springs and recovery springs, and its customers include Volkswagen, ZF and other OEMs and first-class suppliers. Due to operational difficulties, the bankruptcy court in Cologne, Germany, initiated bankruptcy proceedings on the property of AHLE Company on October 1, 2024. Germany Meili purchased these assets by auction, and the transaction price was based on the Financial Due Diligence Report and the Legal Due Diligence Report issued by a third-party intermediary agency, taking into account the market position, channels, customers and future market opportunities of the subject matter of the transaction.Rapdidus will start producing 2-nanometer chips in April next year. Dong Zhelang, president of Rapdidus, an advanced Japanese semiconductor foundry company, said that by the end of March 2025, Rapdidus will complete all the equipment setup required for trial production of 2-nanometer chips, and start the trial production line in April to actually produce 2-nanometer chips.Qianjin Pharmaceutical Co., Ltd.: The subsidiary company obtained the dapoxetine hydrochloride Pharmaceutical Registration Certificate, and Qianjin Pharmaceutical announced that Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the dapoxetine hydrochloride Pharmaceutical Registration Certificate approved and issued by National Medical Products Administration. The medicine is suitable for the treatment of male premature ejaculation patients aged 18 to 64.
Lou Feipeng, a researcher at the Postal Savings Bank: The full implementation of the personal pension system is just the right time for financial institutions to usher in development opportunities. "The full implementation of the personal pension system is just the right time." Lou Feipeng, a researcher at China Postal Savings Bank, said that in the past two years, the personal pension system has achieved remarkable results in general, with a rapid increase in the number of accounts opened and a rapid enrichment of financial products. The data shows that at the end of June 2024, the number of individual pension accounts opened exceeded 60 million. "The implementation of the personal pension system in the pioneering urban areas has enabled the residents to have a more intuitive understanding of the personal pension system. At the same time, it has accumulated rich experience for government departments and financial departments to improve the personal pension system and optimize personal pension financial services. " Yan Feipeng said. (SSE)Dashengda and Tuopai Shede Group set up investment partnerships. According to the enterprise search APP, Sichuan Fujiang Yingke Investment Partnership (Limited Partnership) was recently established with a capital contribution of 200 million yuan. Its business scope includes: asset management services invested by its own funds; Enterprise management consulting; Information technology consulting service. Enterprise equity penetration shows that the enterprise is jointly held by Dashengda and Sichuan Tuopai Shede Group Co., Ltd..Poly Development: Poly Group increased its holdings by 261 million yuan. According to the announcement of Poly Development, the actual controller of the company, Poly Group, has completed the plan to increase its holdings, and accumulated 27,980,100 A shares, accounting for 0.23% of the total share capital, with an increase of 261 million yuan. This increase plan will last for 12 months from December 12, 2023, and the increase amount will be no less than 250 million yuan and no more than 500 million yuan. After the completion of the increase, Poly Group directly holds about 3.03% of the company's shares, and the total shareholding ratio with its wholly-owned subsidiaries is 40.72%. The increase in holdings is in compliance with relevant laws and regulations, and Poly Group promises not to reduce its holdings within the statutory time limit.
President of Hilton Asia Pacific: India's outbound travel will be the story of the next decade. According to the data of the World Tourism and Travel Council, in 2023, Indian tourists spent $34.2 billion on outbound travel. Allen Watts, president of Hilton Asia Pacific, said that compared with the future, the current level of Indian outbound travel consumption is "negligible". "The story of India is unfolding before us," he said. "India's outbound travel will be the story of the next decade." According to the World Tourism and Travel Council's Economic Impact in 2024 report, by 2034, the outbound spending of Indian tourists is expected to more than double, reaching 76.8 billion US dollars, which will make India's position in the global tourism consumption country rise from the 12th in 2023 to the 7th.Hebang Bio established a mining engineering company in Leshan, Sichuan. The enterprise search APP shows that Leshan Hebang Mining Engineering Co., Ltd. was established recently, with Fei Wang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: mineral resources reserve evaluation service; Mineral resources reserve estimation and report preparation services; Geological disaster management services, etc. Enterprise investigation shows that the company is wholly owned by Hebang Bio.In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)